Features | Partner Sites | Information | LinkXpress
Sign In
Samsung
Schiller
Ampronix

MRI Guidance Used in Brain Cancer Drug Injection Procedure

By Medimaging International staff writers
Posted on 19 Aug 2013
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: Using MRI navigation, Dr. Chen injects an investigational gene therapy directly into a brain tumor (Photo courtesy of University of California, San Diego Health Sciences).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Image: The ClearPoint SmartFrame device is a single-use, disposable trajectory frame that is MRI-compatible and enables the MRI-guided alignment and insertion of devices used during ClearPoint procedures (Photo courtesy of MRI Interventions).
Neurosurgeons in California are among the first in the world to utilize real-time magnetic resonance imaging (MRI) guidance for delivery of gene therapy as a potential treatment for brain tumors. Using MRI navigational technology, neurosurgeons can inject Toca 511 (vocimagene amiretrorepvec), a unique investigational gene therapy, directly into a brain tumor. This new application offers a precise way to deliver a therapeutic virus designed to make the tumor vulnerable to cancer-killing drugs.

“With chemotherapy, just about every human cell is exposed to the drug’s potential side-effects. By using the direct injection approach, we believe we can limit the presence of the active drug to just the brain tumor and nowhere else in the body,” said Clark Chen, MD, PhD, chief of stereotactic and radiosurgery and vice-chairman of neurosurgery University of California (UC) San Diego School of Medicine (USA). “With MRI, we can see the tumor light up in real time during drug infusion. The rest of the brain remains unaffected so the risk of the procedure is minimized.”

Toca 511 is a retrovirus engineered to selectively replicate in cancer cells, such as glioblastomas. Toca 511 generates an enzyme that converts an antifungal drug, flucytosine (5-FC), into the anticancer drug 5-fluorouracil (5-FU). After the injection of Toca 511, the patients are treated with an investigational extended-release oral formulation of 5-FC called Toca FC. Cancer cell killing takes place when 5-FC comes into contact with cells infected with Toca 511.

“Inevitably, almost all glioblastoma patients fail currently available therapy. The challenge, in part, is knowing if current drugs are actually penetrating the tumor. This MRI-guided approach will help us deliver this drug into the tumor directly to see if the drug is working,” said Santosh Kesari, MD, PhD, lead investigator and director of neuro-oncology at UC San Diego Moores Cancer Center (USA). “This approach may lead to new treatment options for patients battling several other types of brain cancers.”

Earlier research using gene therapy to treat brain cancer was mostly limited by the failure in delivering the drug into the brain. Under normal conditions, the brain is protected by the blood-brain barrier but this natural defense mechanism also prevents drugs from reaching the cancer cells in patients with brain tumors. Fortunately, 5-FC crosses the blood-brain barrier, and direct injection of Toca 511 into the tumor provides a means to selectively generate chemotherapy within the tumor mass.

To ensure that the adequate amount of Toca 511 is delivered to the region of the tumor, neurosurgeons at UC San Diego Health System utilize state-of-the art MRI guidance, called ClearPoint, to track the delivery and injection processes in real time. The MRI-guided process provides visual validation that the desired amount of drug is delivered into the tumor and provides physicians the ability to make adjustments to optimize the location of drug delivery. The Clearpoint technology was developed by MRI Interventions (Memphis, TN, USA).

Participants in this clinical trial must be 18 years or older; have a single, recurrent Grade 3 or 4 glioma; and have had prior surgery, radiation, and chemotherapy. The MRI-based procedure is minimally invasive and all participants of the study were discharged from the hospital one day after surgery and resumed their normal daily activity.

The phase 1 trial is evaluating the safety and tolerability of Toca 511 in combination with Toca FC (5-FC, extended-release tablets), and is being developed by Tocagen, Inc. (San Diego, CA, USA).

Related Links:

University of California, San Diego Moores Cancer Center
Tocagen
MRI Interventions



Supersonic Imagine
PHS Technologies
ARAB HEALTH

Channels

Radiography

view channel
Image: Coronary CT angiography images demonstrate examples of high-risk plaque features. A, Image was obtained in a 63-year-old man with partially calcified plaque, positive remodeling (vertical arrow), and spotty calcium (horizontal arrow). B, A cross-sectional view of a noncalcified plaque in a 65-year-old man demonstrates a napkin-ring sign with a central low-attenuation area, surrounded by a peripheral rim of higher attenuation (arrow) next to the lumen (∗). C, Image in a 60-year-old woman with partially calcified plaque demonstrates a low CT number in the midportion (arrow) (Photo courtesy of the journal Radiology).

Coronary CT Angiography Reveals Link between Coronary Artery Plaque and Liver Disease

Researchers using coronary computed tomography angiography (CCTA) imaging have found a close correlation between high-risk coronary artery plaque and a common liver disease. The research revealed that... Read more

Nuclear medicine

view channel
Image: The RayPilot placed directly on the original carbon fiber couch (Photo courtesy of Micropos Medical).

Hypofractionated Prostate Radiotherapy Electromagnetic Positioning Tool Tracks Tumors in Real Time During Treatment

A new add-on tool to existing radiotherapy equipment has been designed to track a tumor at any time during the treatment. The system could enable the clinic to enhance precision in their cancer treatment,... Read more

General/Advanced Imaging

view channel

Photoacoustic Imaging Optimizes Visualization of Cancerous Tissues Using Time Reversal Technology

Unique time-reversal technology is being used to better focus light in tissue, such as muscles and organs. Current high-resolution optical imaging technology allows researchers to see about 1-mm-deep into the body. In an effort to enhance this imaging technology, the investigators are employing photoacoustic imaging, which... Read more

Imaging IT

view channel

Use of Radiology Data Mining Tool Reduces Length of Stay for CT Biopsy

Use of a data and analysis tool allows radiology clinical coordinators to facilitate a patient-centered imaging service, acting as a care manager for patients with positive findings on their computed tomography (CT) scans. Syed F. Zaidi, MD, president of Radiology Associates of Canton (RAC; OH, USA) and chief executive... Read more

Industry News

view channel
Image: Zygote’s human anatomy collections (Photo courtesy of Zygote).

Partnership to Provide 3-D Holographic Imaging to Medical Professionals

Zebra Imaging, Inc. (Austin, TX, USA), a provider of three-dimensional (3-D) holographic visualization technologies, reported on a partnership with the Zygote Media Group, Inc. (American Fork, UT, USA),... Read more
 

Events

01 Dec 2014 - 05 Dec 2014
11 Jan 2015 - 14 Jan 2015
Copyright © 2000-2014 Globetech Media. All rights reserved.